CompletedPhase 2NCT04250207
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Studying Corneal dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kowa Research Institute, Inc.
- Principal Investigator
- Shona Pendse, MD, MMScKowa Pharma Development Co.
- Intervention
- K-321 Solution(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (29)
- Jules Stein Eye Institute, Los Angeles, California, United States
- Byers Eye Institute at Stanford, Palo Alto, California, United States
- UC Davis Eye Center, Sacramento, California, United States
- Sacramento Eye Consultants, Sacramento, California, United States
- Gorovoy MD Eye Specialists, Fort Myers, Florida, United States
- UF Health Eye Center, Gainesville, Florida, United States
- Chicago Cornea Consultants Ltd, Hoffman Estates, Illinois, United States
- Arbor Centers For Eyecare, Orland Park, Illinois, United States
- Price Vision Group, Indianapolis, Indiana, United States
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
- W Kellogg Eye Center, Ann Arbor, Michigan, United States
- Minnesota Eye Consultants, Bloomington, Minnesota, United States
- Eye Associates of New Mexico, Albuquerque, New Mexico, United States
- NY Langone Health, New York, New York, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04250207 on ClinicalTrials.govOther trials for Corneal dystrophy
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07217249Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 YearsCase Western Reserve University
- RECRUITINGNANCT07373821Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)University Hospital Heidelberg
- RECRUITINGPHASE2NCT07024693DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyDesign Therapeutics, Inc.
- RECRUITINGNANCT06844123Microsurgical Robot-assisted Corneal TransplantCHU de Reims
- RECRUITINGNANCT06425666Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal DystrophyUniversity of Cologne
- RECRUITINGNCT06966167Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With CataractsEye & ENT Hospital of Fudan University
- RECRUITINGNCT06859411Prognosis of Posterior Lamellar Keratoplasty, an Observational Cohort StudyCentre Hospitalier Régional Metz-Thionville
- RECRUITINGPHASE3NCT05275972Descemet Endothelial Thickness Comparison Trial IIStanford University